RxDoctor Payments Data

Jay Rubin, MD

Ophthalmology · San Antonio, TXNPI 1851386353

Payments from drug & device makers

$137,809in general payments, 2019–2025

Across 39 payments — averaging $3533.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch Health US, LLC$75K
  • Alcon Research LLC$31K
  • Kala Pharmaceuticals, Inc.$27K
  • Novartis$4K
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$248
  • AbbVie$248
  • plus $338 from 4 others

What the payments were for

  • Food & beverage$92598%
  • Education$182%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$137,809 in reported general payments places this provider in the 90th percentile of 1,355 ophthalmology providers in Texas.

See all ophthalmology providers in Texas

Medicare billing

Part B allowed, 2024
$291,042
Medicare patients
1,009
Services billed
3,220

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost246$114,179
RocklatanNetarsudil Mesylat/Latanoprost78$31,119
RestasisCyclosporine26$25,745
VyzultaLatanoprostene Bunod58$23,769
CombiganBrimonidine Tartrate/Timolol44$12,406
Travoprost66$11,059
Cyclosporine22$7,722
Prednisolone Acetate156$6,900
Dorzolamide-TimololDorzolamide/Timolol/Pf28$5,129
Latanoprost524$4,814
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol24$3,237
TafluprostTafluprost/Pf24$2,981
MoxifloxacinMoxifloxacin Hcl134$2,376
Bromfenac Sodium11$1,766
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat118$1,765

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan$248$152,330316 claims
Bausch & Lomb Americas Inc.Vyzulta$43$23,76958 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,355 ophthalmology providers in Texas.

Other ophthalmology in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →